Pharmaceutical combinations and uses for tumor treatment
Patent Information
- Application Number
- JP2024534353
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-02
- Filing Date
- 2022-12-08
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024545147000032 
Figure 2024545147000033 
Figure 2024545147000034
Abstract
Description
[Technical field]
[0001] The present invention is in the field of medicinal chemistry. Specifically, the present invention relates to the combination of focal adhesion kinase (FAK) inhibitors with other drugs to treat tumors. [Background technology]
[0002] Tumors are the second leading cause of death threatening people's health. Immunogenic cell death (ICD) is based on the additive effect of programmed cell death. When cancer cells are exposed to chemotherapy or targeted therapy drugs, they may activate stress signals inside the cells, including endoplasmic reticulum stress (ER stress) and oxidative stress. Under the influence of stress signals, cells first try to repair the stress, but when the damage caused by stress exceeds the repair capacity, the cells start the process of programmed death. This process is usually accompanied by the release of damage associated molecular patterns (DAMPs). Such DAMPs are specifically recognized by pattern recognition receptors in antigen-presenting cells (APCs) in the body, and induce the maturation, differentiation and activation of APCs, and by presenting them stepwise to immune cells such as effector T cells, the immune cells generate antigen memory, and when they find tumor cells of the same origin again, the immune cells specifically recognize and kill the tumor cells. The new specific immune response against tumors initiated by ICD can increase sensitivity to immune checkpoint inhibitors (ICIs), thereby improving the efficacy of immune checkpoint inhibitors and generating antitumor responses with persistent immune memory.
[0003] FAK, also known as protein tyrosine kinase 2 (PTK2), is a non-receptor tyrosine kinase and an important component of focal adhesion complexes. FAK mediates integrin and growth factor signals and plays an important role in regulating tumor cell invasion, proliferation and survival.
[0004] It has been observed that some chemotherapy drugs induce ICD in cancer cells, and ICD is understood to contribute to the antitumor effect of the therapy. Importantly, ICD stimulates the immune system to attack cancer, and can provide a sustained antitumor effect, especially when combined with anti-PD1 or PD-L1. It has also been reported that PLD (doxorubicin hydrochloride liposome injection (doxil)) can induce ICD, but no clinically significant clinical effect was observed in clinical trials, regardless of whether it was used in combination with anti-PD-1 or PD-L1. Western Arizona Regional Medical Center has investigated tumor treatment with anti-PD1 (pembrolizumab) combination chemotherapy (including PLD), but the clinical effect did not meet expectations, and the clinical trial was terminated. Therefore, it is necessary to further search for drugs that can promote the induction of ICD by chemotherapy drugs, improving the response rate of tumor treatment and the possibility of obtaining long-term benefits. Summary of the Invention
[0005] One aspect of the present disclosure provides the use of a FAK inhibitor, an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein the FAK inhibitor, the anthracycline chemotherapeutic agent and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0006] Another aspect of the present disclosure provides a pharmaceutical combination product of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor for treating a tumor in a subject, wherein the FAK inhibitor, the anthracycline chemotherapeutic drug and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0007] One aspect of the present disclosure provides a method for treating a tumor, comprising administering therapeutically effective amounts of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor simultaneously or sequentially to a subject in need thereof.
[0008] Another aspect of the present disclosure provides a kit or a pharma- ceutically acceptable composition comprising: (a) a FAK inhibitor; (b) an anthracycline chemotherapeutic drug; and (c) an immune checkpoint inhibitor.
[0009] Another aspect of the present disclosure provides the use of a FAK inhibitor and an anthracycline chemotherapeutic agent in the manufacture of a medicament for tumor treatment, wherein the FAK inhibitor enhances immunogenic cell death induced by the anthracycline chemotherapeutic agent.
[0010] Another aspect of the present disclosure provides a FAK inhibitor for enhancing immunogenic cell death induced by anthracycline chemotherapeutic agents in the treatment of tumors.
[0011] Another aspect of the present disclosure provides a method for treating tumors, comprising administering to a subject in need thereof, simultaneously or sequentially, therapeutically effective amounts of a FAK inhibitor and an anthracycline chemotherapeutic drug, wherein the FAK inhibitor enhances immunogenic cell death induced by the anthracycline chemotherapeutic drug.
[0012] Another aspect of the present disclosure provides the use of a FAK inhibitor, an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor in the manufacture of a medicament for combination treatment of a tumor.
[0013] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a combination medicament for treating a tumor with an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor.
[0014] Another aspect of the present disclosure provides the use of an anthracycline chemotherapeutic agent in the manufacture of a combination medicament for treating a tumor together with a FAK inhibitor and an immune checkpoint inhibitor.
[0015] Another aspect of the present disclosure provides the use of an immune checkpoint inhibitor in the manufacture of a combination medicament for treating a tumor with a FAK inhibitor and an anthracycline chemotherapeutic agent.
[0016] Another aspect of the present disclosure provides the use of a FAK inhibitor, an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor in the manufacture of a medicament for combination treatment of a tumor.
[0017] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in combination with an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor.
[0018] Another aspect of the present disclosure provides the use of an anthracycline chemotherapeutic agent in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and an immune checkpoint inhibitor.
[0019] Another aspect of the present disclosure provides the use of an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and an anthracycline chemotherapeutic agent.
[0020] Another aspect of the present disclosure provides a kit comprising a FAK inhibitor and a label indicating that the FAK inhibitor can be used in combination with an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor to treat a tumor.
[0021] Another aspect of the present disclosure provides a kit comprising an anthracycline chemotherapeutic agent and a label indicating that the anthracycline chemotherapeutic agent can be used in combination with a FAK inhibitor and an immune checkpoint inhibitor to treat a tumor.
[0022] Another aspect of the present disclosure provides a kit comprising an immune checkpoint inhibitor and a label indicating that the immune checkpoint inhibitor can be used in combination with a FAK inhibitor and an anthracycline chemotherapeutic agent to treat a tumor.
[0023] Another aspect of the present disclosure provides a method for treating a tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a FAK inhibitor and an anthracycline chemotherapeutic agent.
[0024] Another aspect of the present disclosure provides a pharmaceutical combination product of a FAK inhibitor and an anthracycline chemotherapeutic agent for the treatment of tumors in a subject in need thereof.
[0025] Another aspect of the present disclosure provides the use of a FAK inhibitor and an anthracycline chemotherapeutic agent in the manufacture of a medicament combination for treating a tumor.
[0026] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a combination medicament for treating a tumor with an anthracycline chemotherapeutic agent.
[0027] Another aspect of the present disclosure provides the use of an anthracycline chemotherapeutic agent in the manufacture of a combination medicament for treating a tumor together with a FAK inhibitor.
[0028] Another aspect of the present disclosure provides the use of a FAK inhibitor and an anthracycline chemotherapeutic agent in the manufacture of a medicament for the combination treatment of a tumor.
[0029] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in combination with an anthracycline chemotherapeutic agent.
[0030] Another aspect of the present disclosure provides the use of an anthracycline chemotherapeutic agent in combination with a FAK inhibitor in the manufacture of a medicament for treating a tumor.
[0031] Another aspect of the present disclosure provides a kit comprising a FAK inhibitor and a label indicating that the FAK inhibitor can be used in combination with an anthracycline chemotherapeutic agent to treat a tumor.
[0032] Another aspect of the present disclosure provides a kit comprising an anthracycline chemotherapeutic agent and a label indicating that the anthracycline chemotherapeutic agent can be used in combination with a FAK inhibitor to treat a tumor.
[0033] One aspect of the present disclosure provides the use of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein the FAK inhibitor, the doxorubicin and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0034] Another aspect of the present disclosure provides a pharmaceutical combination product of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor for treating a tumor in a subject, wherein said FAK inhibitor, said doxorubicin and said immune checkpoint inhibitor are administered to said subject simultaneously or sequentially.
[0035] One aspect of the present disclosure provides a method for treating tumors, comprising administering therapeutically effective amounts of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor simultaneously or sequentially to a subject in need thereof.
[0036] Another aspect of the present disclosure provides a kit or a pharma- ceutically acceptable composition comprising: (a) a FAK inhibitor; (b) doxorubicin; and (c) an immune checkpoint inhibitor.
[0037] Another aspect of the present disclosure provides the use of a FAK inhibitor and doxorubicin in the manufacture of a medicament for treating a tumor, wherein the FAK inhibitor enhances immunogenic cell death induced by the doxorubicin.
[0038] Another aspect of the present disclosure provides a FAK inhibitor that enhances doxorubicin-induced immunogenic cell death in the treatment of tumors.
[0039] Another aspect of the present disclosure provides a method for treating tumors comprising simultaneously or sequentially administering to a subject in need thereof therapeutically effective amounts of a FAK inhibitor and doxorubicin, wherein the FAK inhibitor enhances immunogenic cell death induced by the doxorubicin.
[0040] Another aspect of the present disclosure provides the use of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor in the manufacture of a medicament for combination treatment of a tumor.
[0041] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a combination medicament for treating a tumor with doxorubicin and an immune checkpoint inhibitor.
[0042] Another aspect of the present disclosure provides the use of doxorubicin in the manufacture of a combination medicament for treating a tumor with a FAK inhibitor and an immune checkpoint inhibitor.
[0043] Another aspect of the present disclosure provides the use of an immune checkpoint inhibitor in the manufacture of a combination medicament for treating a tumor with a FAK inhibitor and doxorubicin.
[0044] Another aspect of the present disclosure provides the use of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor in the manufacture of a medicament for combination treatment of a tumor.
[0045] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in combination with doxorubicin and an immune checkpoint inhibitor.
[0046] Another aspect of the present disclosure provides the use of doxorubicin in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and an immune checkpoint inhibitor.
[0047] Another aspect of the present disclosure provides the use of an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and doxorubicin.
[0048] Another aspect of the present disclosure provides a kit comprising a FAK inhibitor and a label indicating that the FAK inhibitor can be used in combination with doxorubicin and an immune checkpoint inhibitor to treat tumors.
[0049] Another aspect of the present disclosure provides a kit comprising doxorubicin and a label indicating that the doxorubicin can be used in combination with a FAK inhibitor and an immune checkpoint inhibitor to treat a tumor.
[0050] Another aspect of the present disclosure provides a kit comprising an immune checkpoint inhibitor and a label indicating that the immune checkpoint inhibitor can be used in combination with a FAK inhibitor and doxorubicin to treat a tumor.
[0051] Another aspect of the present disclosure provides a method for treating tumors, comprising administering to a subject in need thereof a therapeutically effective amount of a FAK inhibitor and doxorubicin.
[0052] Another aspect of the present disclosure provides a pharmaceutical combination product of a FAK inhibitor and a doxorubicin chemotherapeutic agent for the treatment of tumors in a subject in need thereof.
[0053] Another aspect of the present disclosure provides the use of a FAK inhibitor and doxorubicin in the manufacture of a combination medicament for treating a tumor.
[0054] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a combination medicament for treating a tumor with doxorubicin.
[0055] Another aspect of the present disclosure provides the use of doxorubicin in the manufacture of a combination medicament for treating a tumor with a FAK inhibitor.
[0056] Another aspect of the present disclosure provides the use of a FAK inhibitor and doxorubicin in the manufacture of a medicament for the combination treatment of a tumor.
[0057] Another aspect of the present disclosure provides the use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in combination with doxorubicin.
[0058] Another aspect of the present disclosure provides the use of doxorubicin in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor.
[0059] Another aspect of the present disclosure provides a kit comprising a FAK inhibitor and a label indicating that the FAK inhibitor can be used in combination with doxorubicin to treat tumors.
[0060] Another aspect of the present disclosure provides a kit comprising doxorubicin and a label indicating that the doxorubicin can be used in combination with a FAK inhibitor to treat a tumor.
[0061] Alternatively, the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0062] The defactinib is also called defactinib, and has a CAS number of 1345713-71-4, the GSK2256098 has a CAS number of 1224887-10-8, the PF-00562271 has a CAS number of 717907-75-0, the VS-4718 has a CAS number of 1061353-68-1, the APG-2449 is developed by Yashen Pharmaceutical, and the AMP945 has a CAS number of 1393653-34-3.
[0063] Alternatively, the anthracycline chemotherapeutic agent is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0064] Alternatively, the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor, or a TIGIT inhibitor.
[0065] Alternatively, the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, for example, the anti-PD-1 / PD-L1 antibody is pembrolizumab, tislelizumab, nivolumab, toripalimab, atezolizumab, durvalumab, avelumab, camrelizumab, sintilimab, cemiplimab, envafolimab, BMS-936559, JS003, SHR-1316, GS-4224, AN-4005 or MX-10181, in particular toripalimab.
[0066] Alternatively, the immune checkpoint inhibitor is a PD-1 / PD-L1 small molecule inhibitor, for example, the PD-1 / PD-L1 small molecule inhibitor is INCB-086550, Lazertinib, IMMH-010, CA-170, ABSK043 or RRx-001.
[0067] Alternatively, the immune checkpoint inhibitor is a TIGIT inhibitor, for example, the TIGIT inhibitor is Ociperlimab (BGB-A1217), Vibostolimab, domvanalimab (AB154), Tiragolumab, Belrestotug, Etigilimab, ONO-4686, JS-006, AZD-2936, HLX-301, SEA-TGT, M-6223, IBI-939, COM-902, AB-308, AGEN-1777, AK-127, BAT-6021, BAT-6005, ASP-8374, PM-1022, BMS-986207, HB0036 or IBI-321.
[0068] Alternatively, the tumor is Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer, or laryngeal cancer. Further, the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or bile duct cancer, and further, ovarian cancer or colon cancer. [Brief description of the drawings]
[0069] In order to more clearly describe the technical solutions of the embodiments of the present disclosure, the drawings related to the embodiments are briefly described below. Obviously, the drawings described below are only related to some embodiments of the present disclosure, and are not intended to limit the present invention.
[0070] [Figure 1] The effect of knocking out FAK and phosphorylated FAKY397 by FAK siRNA is shown. [Diagram 2] 1 shows the synergistic killing effect of the combination of 3 μM doxorubicin and 50 nM FAK siRNA knockout on ovarian cancer cells SK-OV-3. [Diagram 3] Immunofluorescence staining of DAMPs after a combination of 3 μM doxorubicin and 50 nM FAK siRNA for 48 hours is shown. [Figure 4] 72-hour killing curves and IC50 values of IN10018 and doxorubicin against ovarian cancer cells SK-OV-3. [Diagram 5] 1 shows the synergistic killing effect of ovarian cancer cells SK-OV-3 after combination of different doses of doxorubicin and 3 μM IN10018 for 48 hours. [Figure 6] The results are shown as staining with the Annexin V kit after a combination of 0.3 or 1.0 μM doxorubicin and 3 μM IN10018 for 48 hours. [Figure 7] Immunofluorescence staining of DAMPs after a combination of 0.3 μM doxorubicin and 3 μM IN10018 for 48 hours is shown. [Figure 8] The results of immunofluorescence staining of DAMPs after combining 0.3 μM Daunorubicin or Epirubicin with 3 μM IN10018 for 48 hours are shown. [Figure 9] 1 shows the synergistic killing effect of doxorubicin at different doses in combination with 3 μM defactinib for 72 hours on ovarian cancer cells SK-OV-3. [Figure 10] The results of immunofluorescence staining of DAMPs after a combination of 1 μM doxorubicin and 3 μM defactinib for 48 hours are shown. [Figure 11] White light micrographs of cells taken after incubating the cells with drugs for 48 hours are shown. [Figure 12]Figure 12 shows the percentage of CRT-positive and Annexin V-positive CT26 cells after incubation with IN10018 and doxorubicin for 48 hours; Figure 12a shows the percentage of CRT-positive CT26 cells after incubation with the drugs for 48 hours, and Figure 12b shows the percentage of Annexin V-positive CT26 cells after incubation with the drugs for 48 hours. [Figure 13] Figure 1 shows changes in tumor growth following administration of different test substances in tumor-bearing mice in a BALB / c mouse homograft tumor model of murine colon cancer CT26. Data points represent mean ± standard error within groups, n=8. [Figure 14] Figure 1 shows the weight change status of mice after administration of different doses of drugs and the weight change of mice after administration of different doses of drugs. Data points represent the mean ± standard error within the group, n=8. [Figure 15] 1 shows changes in tumor growth following administration of different test substances in tumor-bearing mice in a BALB / c mouse homograft tumor model of murine colon cancer CT26. Data points represent mean ± standard error within groups, n=8. [Figure 16] Figure 1 shows the weight change status of mice after administration of different doses of drugs and the weight change of mice after administration of different doses of drugs. Data points represent the mean ± standard error within the group, n=8. [Figure 17] Shown are IFN-γ protein concentrations detected in serum isolated from orbital blood samples taken after 7 days of treatment with CT26 murine colon carcinoma cells in a BALB / c mouse subcutaneous homograft tumor model. [Figure 18] The figure shows the concentration of Granzyme B protein detected in serum separated from blood taken from the orbit after 7 days of administration of CT26 mouse colon cancer cells in a subcutaneous homograft tumor model in BALB / c mice. [Figure 19] The percentages of CRT-positive and Annexin V-positive 4T1 cells after 48 hours of incubation with doxorubicin and AMP945 are shown. FIG. 19a shows the percentage of CRT-positive 4T1 cells after 48 hours of incubation with the drugs, and FIG. 19b shows the percentage of Annexin V-positive 4T1 cells after 48 hours of incubation with the drugs. [Figure 20] The percentages of CRT-positive and Annexin V-positive CT26 cells after incubation with doxorubicin and AMP945 for 48 hours are shown. FIG. 20a shows the percentage of CRT-positive CT26 cells after incubation with the drugs for 48 hours, and FIG. 20b shows the percentage of Annexin V-positive CT26 cells after incubation with the drugs for 48 hours. [Figure 21] 1 shows a waterfall plot of best % change in total diameter of target lesions versus baseline in a clinical study of IN10018 in combination with PLD and anti-PD-1 to treat ovarian cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0071] In order to make the objectives, technical means and advantages of the embodiments of the present disclosure clearer, the technical means of the embodiments of the present disclosure will be clearly and completely described below with reference to the drawings of the embodiments of the present disclosure. Obviously, the described embodiments are only a part of the embodiments of the present disclosure, and are not all of the embodiments. Based on the described embodiments of the present disclosure, any other embodiments that a person skilled in the art can obtain without creative labor are all within the scope of protection of the present invention.
[0072] The present invention may be embodied in other specific forms without departing from the essential attributes of the present invention. It should be understood that, unless inconsistent, any and all embodiments of the present invention may be combined with the technical features of any one or more other embodiments to obtain another embodiment. The present invention includes the other embodiment obtained from such combination.
[0073] All publications and patents mentioned in this disclosure are incorporated herein by reference in their entirety. In the event that the application or terminology used in any publication or patent incorporated by reference conflicts with the application or terminology used in this disclosure, the application and terminology in this disclosure shall control.
[0074] The section headings used herein are used for organizational purposes only and are not to be construed as limiting the subject matter discussed above.
[0075] Unless otherwise defined, all technical and scientific terms used herein have their common meaning within the field to which the subject matter sought to be protected. In the event that a term has a plurality of definitions, those in this specification are the prevailing definition.
[0076] All numerical values of quantitative properties, such as dosages, set forth in the specification and claims, except in the examples or where otherwise indicated, should be understood to be modified in all instances by the term "about." It should be noted that any numerical range recited in this application is intended to include all subranges within that range and any combination of each endpoint of that range or subrange.
[0077] As used in this disclosure, words such as "comprise", "contain", or "comprise" and similar words are intended to cover the elements listed after the word and their equivalents, and not to exclude elements not listed. As used herein, the term "comprise" or "comprise" may be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0078] definition The following terms and symbols used in this application have the meanings given below, unless otherwise indicated by the context in which they are placed. The term "FAK inhibitor" as used herein refers to an effective inhibitor of FAK, suitable for mammals, particularly humans. In some embodiments, the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharmaceutically acceptable salt thereof, and the structure of IN10018 is as follows: [ka]
[0079] The defactinib is also called defactinib, and has a CAS number of 1345713-71-4, and the GSK2256098 has a CAS number of 1224887-10-8. The PF-00562271 has a CAS number of 717907-75-0, the VS-4718 has a CAS number of 1061353-68-1, the APG-2449 is developed by Yasheng Pharmaceutical, and the AMP945 has a CAS number of 1393653-34-3. In some embodiments, the FAK inhibitor is preferably IN10018, defactinib, AMP945 or a pharmaceutical acceptable salt thereof, and in some preferred embodiments, the FAK inhibitor is IN10018 or a pharmaceutical acceptable salt thereof, particularly IN10018 tartrate.
[0080] The term "anthracycline drug" as used herein refers to a chemotherapy drug derived from Streptomyces piucetius var. aureus. In some embodiments, the anthracycline drug is doxorubicin, epirubicin, daunorubicin, or aclarubicin. In some preferred embodiments, the anthracycline drug is doxorubicin.
[0081] The term "doxorubicin" used in this specification means Doxorubicin, and the technical method of the present invention only refers to doxorubicin, but it is understood that doxorubicin or its different salts or preparations are all protected. For example, PLD refers to doxorubicin hydrochloride liposome injection (doxil), which is a doxorubicin hydrochloride liposome injection, and its active ingredient is doxorubicin.
[0082] As used herein, the term "immune checkpoint inhibitor" refers to a drug that can improve immune system activity by modulating immune checkpoint pathways (e.g., PD-1, TIGIT, CTLA-4, LAG-3, TIM-3, etc.). In some embodiments, the immune checkpoint inhibitor is an antagonist of the PD-1 / PD-L1 (programmed cell death protein 1) pathway (also referred to as a "PD-1 inhibitor") or a TIGIT inhibitor. PD-1 inhibitors are also referred to as PD-1 / PD-L1 inhibitors in this disclosure. For example, in the therapeutic methods, medicaments and uses of the present disclosure, the PD-1 / PD-L1 inhibitor is an anti-PD-1 / PD-L1 antibody, including, but not limited to, pembrolizumab (Keytruda / K), tislelizumab (Tislelizumab / Hyakuzawayasu), nivolumab, toripalimab (Toripalimab / Takuei), durvalumab (Imfinzi / durvalumab), avelumab (Avelumab / Bavencio), atezolizumab (MPDL3280A / Atezolizumab / Tecentriq / T), BMS-936559 (fully human anti-PD-L1 IgG4 monoclonal antibody), GS-4224, AN-4005 or MX-10181, in particular toripalimab. In some preferred embodiments, the PD-1 inhibitor is toripalimab. In some embodiments, PD-1 inhibitors are used to treat human subjects. In some embodiments, PD-1 is human PD-1. PD-1 / PD-L1 inhibitors also include PD-1 / PD-L1 small molecule inhibitors, such as INCB-086550, Lazertinib, IMMH-010, CA-170, ABSK043, or RRx-001. TIGIT (also known as WUCAM, Vstm3, VSIG9) is a receptor of the Ig superfamily and a novel immune checkpoint that follows PD-1 / PD-L1.For example, in the therapeutic methods, drugs, and uses disclosed herein, the immune checkpoint inhibitor is a TIGIT inhibitor (e.g., a TIGIT antibody), and examples thereof include osiperlimab (BGB-A1217), vibostolimab, domvanalimab (AB154), tiragolumab, belrestotug, etigilimab ( Etigilimab), ONO-4686, JS-006, AZD-2936, HLX-301, SEA-TGT, M-6223, IBI-939, COM-902, AB-308, AGEN-1777, AK-127, BAT-6021, BAT-6005, ASP-8374, PM-1022, BMS-986207, HB0036, or IBI-321. In some embodiments, the TIGIT inhibitor is used to treat a human subject. For the avoidance of doubt, any reference to an antibody herein includes a biantibody.
[0083] As used herein, a "pharmaceutical combination" or "pharmaceutical combination product" may refer to a fixed combination in one dosage unit form (e.g., all active pharmaceutical ingredients are present in one dosage form) or a product that is administered in combination using a kit, or may refer to a combination of one drug and a label indicating that the drug can be used in combination with one or more other drugs.
[0084] As used herein, "combination therapy" or "combination drug" refers to the use of one drug in combination with one or more other drugs to treat a disease, and includes not only the combination of one drug with one or more other drugs, but also the combination of one drug with a label indicating that the drug can be used in combination with one or more other drugs.
[0085] "Administered simultaneously or sequentially" in the present application refers to administering two or more drugs simultaneously or one after the other with a certain time interval within one administration cycle (e.g., within 4 weeks, 3 weeks, 2 weeks, 1 week, or within 24 hours), and the administration method of the drugs (e.g., oral administration, intravenous administration, intramuscular administration, subcutaneous administration, etc.) may be the same or different, and the administration frequency / cycle of the two or more drugs may be the same or different. When the treatment method, product, or use of the present disclosure relates to two drugs, the two drugs may be administered simultaneously or separately with a certain time interval. When the treatment method, product, or use of the present disclosure relates to three drugs, the three drugs may be administered at the same time point, two drugs may be administered at one time point and the remaining one drug may be administered at another time point, or all three drugs may be administered at different times.
[0086] In some embodiments, the PD-1 / PD-L1 inhibitor is administered intravenously (e.g., by intravenous infusion), or subcutaneously, or orally. Preferably, the PD-1 / PD-L1 inhibitor is administered by intravenous infusion.
[0087] The cancer therapeutic potential of immune checkpoint inhibitors depends on the presence of tumor antigen-specific T cells in tumor tissue. This requires that tumor tissue expresses antigens that distinguish it from its non-transformed counterpart, for example, through novel protein products called neoantigens. Tumor neoantigen load is closely related to immunogenicity and sensitivity (e.g., to checkpoint inhibitor therapy), which means that tumors with poor immunogenicity should be largely resistant to these drugs. Treatments to release tumor antigens that can be ingested by APCs, for example, treatments to induce immunogenic cell death (ICD), may promote effective antitumor immunity, especially when combined with checkpoint inhibitors.
[0088] As used herein, the term "treatment" refers to the administration of one or more drug substances to a subject having a disease or a symptom of said disease to cure, alleviate, relieve, alter, treat, ameliorate, improve or affect said disease or a symptom of said disease. In some embodiments, said disease is a tumor or cancer.
[0089] The term "tumor" as used herein refers to an abnormal lesion formed by the cell of local tissue losing the normal regulation of its proliferation at the genetic level under the action of various tumorigenic factors, resulting in its clonal abnormal proliferation.Examples include, but are not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer. Further, the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or bile duct cancer, and further, ovarian cancer or colon cancer.
[0090] The term "subject" or "subject" as used herein refers to mammals and non-mammals. Mammals refer to any member of the mammalian species, including, but not limited to, humans, non-human primates such as chimpanzees and other ape and monkey species, farm animals such as cows, horses, sheep, goats, pigs, livestock such as rabbits, dogs, cats, and laboratory animals including rodents such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, and the like. The term "subject" is not limited to a particular age or sex. In some embodiments, the subject is a human.
[0091] As used herein, the term "pharmaceutical acceptable" refers to non-toxic, biologically tolerable, and suitable for administration to a subject.
[0092] The term "pharmaceutically acceptable salts" as used herein refers to non-toxic, biologically acceptable acid addition salts suitable for administration to a subject, including, for example, acid addition salts formed with inorganic acids, such as hydrochlorides, hydrobromides, carbonates, bicarbonates, phosphates, sulfates, sulfites, nitrates, and the like, as well as, for example, formates, acetates, malates, maleates, fumarates, tartrates, succinates, citrates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethanesulfonates, benzoates, salicylates, stearates, and salts of the formula HOOC-(CH 2 ) n These include, but are not limited to, acid addition salts formed with organic acids, such as salts of -COOH (n is 0-4) formed with alkanedicarboxylic acids.
[0093] Pharmaceutically acceptable acid addition salts can also be obtained by dissolving the free base in a suitable solvent and treating the solution with an acid, following the standard procedure for preparing an acid addition salt from a basic compound. Those skilled in the art can determine, without undue experimentation, synthetic methods for preparing a variety of non-toxic pharma- ceutically acceptable acid addition salts.
[0094] The term "pharmaceutical acceptable composition" as used herein means that it must be chemically and / or toxicologically compatible with other ingredients comprising the formulation and / or the subject being treated therewith. The term "therapeutically effective amount" as used herein refers to an amount sufficient to provide a beneficial therapeutic effect to the subject. The therapeutically effective amount of the present invention can be determined by a combination of conventional methods (e.g., modeling, dose escalation studies or clinical trials) and conventional influencing factors (e.g., method of administration, pharmacokinetics of the compound, severity and course of the disease, medical history of the subject, health status of the subject, responsiveness of the subject to the drug, etc.).
[0095] As used herein, the term "inhibition" refers to a reduction in the baseline activity of a biological activity or process.
[0096] The term "kit" as used herein refers to a box for containing chemical reagents for detecting chemical components, drug residues, types of viruses, etc. The kit according to the present invention includes (i) one, two or three of a FAK inhibitor, an anthracycline chemotherapeutic drug (e.g., doxorubicin), and an immune checkpoint inhibitor, and (ii) a description of the efficacy, which describes that the FAK inhibitor, the anthracycline chemotherapeutic drug, and the immune checkpoint inhibitor can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) a FAK inhibitor, and (ii) a description of the efficacy, which describes that the FAK inhibitor, the anthracycline chemotherapeutic drug, and the immune checkpoint inhibitor can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) an anthracycline chemotherapeutic drug, and (ii) a description of the efficacy, which describes that the FAK inhibitor, the anthracycline chemotherapeutic drug, and the immune checkpoint inhibitor can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) an immune checkpoint inhibitor and (ii) a label describing that the FAK inhibitor, an anthracycline chemotherapeutic agent, and an immune checkpoint inhibitor can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) an FAK inhibitor, an anthracycline chemotherapeutic agent, and an immune checkpoint inhibitor and (ii) a label describing that the FAK inhibitor, an anthracycline chemotherapeutic agent, and an immune checkpoint inhibitor can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) an FAK inhibitor and (ii) a label describing that the FAK inhibitor and an anthracycline chemotherapeutic agent can be used to treat a tumor in a subject. In one embodiment, the kit includes (i) an anthracycline chemotherapeutic agent and (ii) a label describing that the anthracycline chemotherapeutic agent and an FAK inhibitor can be used to treat a tumor in a subject.
[0097] The compounds of the kit may be contained in separate containers. Alternatively, two or more compounds may be contained in the same container. For example, the kit includes a first container, a second container, a third container, and a package insert, the first container includes at least one dose of a drug comprising a FAK inhibitor, the second container includes at least one dose of an anthracycline chemotherapeutic drug (e.g., doxorubicin), the third container includes at least one dose of a drug comprising an immune checkpoint inhibitor, and the package insert includes instructions for using the drug to treat a tumor in a subject. The first container, the second container, and the third container may include the same or different shapes (e.g., vials, syringes, and bottles) and / or materials (e.g., plastic or glass). The kit may further include other materials that may contribute to the administration of the drug, such as diluents, filters, IV bags, pipelines, needles, and syringes.
[0098] The exact amount of FAK inhibitor, anthracycline drug, or immune checkpoint inhibitor administered to a subject depends on various factors, such as the given drug or compound, pharmaceutical formulation, route of administration, disease type, disease symptoms, identity of the subject or host being treated, but may still be generally determined by those skilled in the art. For example, determining the effective amount also depends on the degree, severity and type of cell proliferation. Those skilled in the art can determine the appropriate dosage based on these and other factors.
[0099] The FAK inhibitor, anthracycline drug, or immune checkpoint inhibitor can be administered by an appropriate method, such as oral administration, intravenous administration, intramuscular administration, or subcutaneous administration.
[0100] For example, for oral administration, the drug can be orally administered with a pharma- ceutically acceptable carrier, such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft gelatin capsules, compressed into tablets, or mixed directly with the patient's food. For example, the drug can be combined with one or more excipients and used in the form of ingestible tablets, oral tablets, lozenges, capsules, elixirs, suspensions, syrups, or capsules of sticky rice paper. Tablets, lozenges, pills, capsules, etc. can further include adhesives such as tragacanth, gum arabic, corn starch, or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch, potato starch, alginic acid, lubricants such as magnesium stearate, or sweeteners such as sucrose, fructose, lactose, or aspartame, or flavorings.
[0101] For example, for administration by intravenous or intraperitoneal infusion or injection, solutions of the drug can be prepared in water, optionally mixed with a nontoxic surfactant.
[0102] Exemplary pharmaceutical dosage forms for injection or infusion include sterile aqueous solutions, dispersions, or sterile powders containing the active ingredient, which are suitable for the extemporaneous manufacture of sterile injectable or infusible solutions or dispersions. In any case, the ultimate dosage form must be sterile, fluid, and stable under the manufacture and storage conditions.
[0103] Sterile injectable solutions can be prepared by mixing the required amount of the drug and various other required ingredients listed above in a suitable solvent, followed by sterilization by filtration. For sterile powders for the preparation of sterile injectable solutions, the preferred preparation method may be vacuum drying and freeze-drying techniques, which yield powders of the active ingredient and any other desired ingredients present after previously sterile filtration.
[0104] The amount of FAK inhibitor, anthracycline drug, or immune checkpoint inhibitor required for treatment will vary depending on the particular reagent selected, as well as the route of administration, the nature of the disease being treated, and the age and condition of the patient, and can ultimately be determined at the discretion of the attending physician or clinician. Generally, however, the dosage may be within the range of about 0.1 to about 50 mg / kg body weight per day.
[0105] The FAK inhibitor is administered in a dosage range of 5 mg / day to 300 mg / day for adults. In one specific embodiment, IN10018 or a pharma- ceutically acceptable salt thereof is administered in a dosage range of 5 mg / day to 100 mg / day for adults, said dosages being calculated on the free base.
[0106] The anthracycline drug is administered weekly in the range of 1 to 40 mg / m2 for adults. 2 In one specific embodiment, doxorubicin or a pharma- ceutically acceptable salt thereof is administered at a dose range of 1 to 40 mg / m weekly for adults. 2 and the dose is calculated in doxorubicin.
[0107] The immune checkpoint inhibitor is administered at a dose of 2 to 10 mg / kg or 50 to 1200 mg for adults each time, once every 2 to 3 weeks. In one specific embodiment, the immune checkpoint inhibitor is administered at a dose of 3 to 10 mg / kg or 100 to 1200 mg for adults each time, once every 2 to 3 weeks.
[0108] Technical and scientific terms used herein that are not specifically defined have the meanings commonly understood by those of ordinary skill in the art.
[0109] In some embodiments, the present disclosure further discloses:
[0110] 1. A FAK inhibitor, an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor for a method of treating a tumor in a subject, wherein the FAK inhibitor, the anthracycline chemotherapeutic agent and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0111] 2. The compound for said use according to embodiment 1, wherein said FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and wherein the structure of said IN10018 is as follows: [ka]
[0112] 3. The compound for said use according to embodiment 1 or 2, wherein said anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0113] 4. The compound for said use according to any one of embodiments 1 to 3, wherein said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
[0114] 5. The compound for said use according to any one of embodiments 1 to 4, wherein said FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, said anthracycline drug is doxorubicin, and said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
[0115] 6. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal junction cancer. 6. The compound for said use according to any one of embodiments 1 to 5, wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0116] 7.(a) A FAK inhibitor; (b) an anthracycline drug; (c) an immune checkpoint inhibitor.
[0117] 8. The kit or composition of embodiment 7, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0118] 9. The kit or composition of embodiment 7 or 8, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0119] 10. The kit or composition according to any one of embodiments 7 to 9, wherein the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor, or a TIGIT inhibitor.
[0120] 11. The kit or composition according to any one of embodiments 7 to 10, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline is doxorubicin, and the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor, in particular toripalimab.
[0121] 12. A kit or composition according to any one of embodiments 7 to 11 for use as a medicament.
[0122] 13. A kit or composition according to any one of embodiments 7 to 12 for treating a tumor.
[0123] 14. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastric cancer. The kit or composition of embodiment 13, wherein the tumor is esophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0124] 15. A method for treating a tumor in a subject, comprising the step of simultaneously or sequentially administering to said subject the compounds of the kit or composition according to any one of embodiments 7 to 12.
[0125] 16. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, and esophageal cancer. 16. The method of embodiment 15, wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer, or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0126] 17. FAK inhibitors to enhance immunogenic cell death induced by anthracyclines.
[0127] 18. The FAK inhibitor for use according to embodiment 17, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0128] 19. The FAK inhibitor for use according to embodiment 17 or 18, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0129] 20. The FAK inhibitor for use according to any one of embodiments 17 to 19, wherein the FAK inhibitor and the anthracycline drug are administered simultaneously or sequentially.
[0130] 21. A method for treating a tumor in a subject, comprising the step of simultaneously or sequentially administering to the subject therapeutically effective amounts of a FAK inhibitor, an anthracycline drug and an immune checkpoint inhibitor.
[0131] 22. The method of embodiment 21, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0132] 23. The method of embodiment 21 or 22, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0133] 24. The method of any one of embodiments 21 to 23, wherein the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor.
[0134] 25. The method of any one of embodiments 21-24, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline is doxorubicin, and the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor, in particular toripalimab.
[0135] 26. The tumor is Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, or esophageal cancer. , gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further, the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further, ovarian cancer or colon cancer.
[0136] 27. A FAK inhibitor, an anthracycline drug and an immune checkpoint inhibitor for a method of treating a tumor by increasing immunogenic cell death in a subject, wherein the FAK inhibitor, the anthracycline drug and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0137] 28. The compound for said use according to embodiment 27, wherein said FAK inhibitor is IN10018, defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and wherein the structure of said IN10018 is as follows: [ka]
[0138] 29. The method of embodiment 27 or 28, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0139] 30. The compound for said use according to any one of embodiments 27 to 29, wherein said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
[0140] 31. The compound for said use according to any one of embodiments 27 to 30, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline drug is doxorubicin, and the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor.
[0141] 32. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal junction cancer. The compound of any one of embodiments 27 to 31, wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0142] 33. A method for treating a tumor by increasing immunogenic cell death in a subject, the method comprising the step of simultaneously or sequentially administering to the subject therapeutically effective amounts of a FAK inhibitor, an anthracycline drug and an immune checkpoint inhibitor.
[0143] 34. The method of embodiment 33, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0144] 35. The method of embodiment 33 or 34, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0145] 36. The method of any one of embodiments 33 to 35, wherein the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor, or a TIGIT inhibitor.
[0146] 37. The method of any one of embodiments 33-36, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline drug is doxorubicin, and the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
[0147] 38. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal cancer. The method according to any one of embodiments 33 to 37, wherein the tumor is junctional cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0148] 39. Use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein the FAK inhibitor, an anthracycline drug and an immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
[0149] 40. The use according to embodiment 39, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0150] 41. The use according to embodiment 39 or 40, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0151] 42. The use according to any one of embodiments 39 to 41, wherein the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor.
[0152] 43. The use according to any one of embodiments 39 to 42, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline is doxorubicin, and the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor, in particular toripalimab.
[0153] 44. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal cancer. Use according to any one of embodiments 39 to 43, wherein the tumor is junctional cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0154] 45. Use of an anthracycline drug in the manufacture of a medicament for treating a tumor in a subject, wherein a FAK inhibitor, the anthracycline drug and an immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
[0155] 46. The use according to embodiment 45, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0156] 47. The use according to embodiment 45 or 46, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0157] 48. The use according to any one of embodiments 45 to 47, wherein the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
[0158] 49. The use according to any one of embodiments 45 to 48, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline drug is doxorubicin, and the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
[0159] 50. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal cancer. The use according to any one of embodiments 45 to 49, wherein the tumor is junctional cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
[0160] 51. Use of an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein a FAK inhibitor, an anthracycline drug and the immune checkpoint inhibitor are administered to the subject simultaneously or sequentially.
[0161] 52. Use of a FAK inhibitor, an anthracycline chemotherapeutic agent and an immune checkpoint inhibitor in the manufacture of a combination medicament for treating a tumor.
[0162] 53. Use of a FAK inhibitor in the manufacture of a combination therapy for treating a tumor together with an anthracycline chemotherapy drug and an immune checkpoint inhibitor.
[0163] 54. Use of an anthracycline chemotherapy agent in the manufacture of a combination therapy for treating a tumor together with a FAK inhibitor and an immune checkpoint inhibitor.
[0164] 55. Use of an immune checkpoint inhibitor in the manufacture of a combination therapy for treating a tumor together with a FAK inhibitor and an anthracycline chemotherapy drug.
[0165] 56. Use of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor in the manufacture of a drug for combined tumor treatment.
[0166] 57. Use of a FAK inhibitor in the manufacture of a medicament for treating a tumor in combination with an anthracycline chemotherapy drug and an immune checkpoint inhibitor.
[0167] 58. Use of an anthracycline chemotherapy drug in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and an immune checkpoint inhibitor.
[0168] 59. Use of an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in combination with a FAK inhibitor and an anthracycline chemotherapy drug.
[0169] 60. The use according to any one of embodiments 51 to 59, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [ka]
[0170] 61. The use according to any one of embodiments 51 to 60, wherein the anthracycline drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
[0171] 62. The use according to any one of embodiments 51 to 61, wherein the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
[0172] 63. The use according to any one of embodiments 51 to 62, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline drug is doxorubicin, and the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
[0173] 64. The tumor is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal cancer. Use according to any one of embodiments 51 to 63, wherein the tumor is junctional cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, uveal melanoma, skin cancer, germ cell cancer, nasopharyngeal cancer, oropharyngeal cancer or laryngeal cancer, and further wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer. EXAMPLES
[0174] The present invention will be further described below by providing examples. It should be understood that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention.
[0175] In the following examples, all experimental methods for which no specific conditions are specified are carried out under general conditions for such reactions or under conditions recommended by the manufacturer.
[0176] All experimental materials and reagents used in the following examples are commercially available unless otherwise specified.
[0177] The abbreviations used in the examples have the following meanings: [Table 1]
[0178] Example 1: Studies on FAK knockout enhances immunogenic cell death of ovarian cancer cells in response to doxorubicin Experimental Design: 1) FAK knockout by FAK siRNA and detection of knockout efficiency SK-OV-3 cells were used as the study subjects, and 50 nM FAK siRNA was transfected using Lipofectamine 3000. After the experiment, proteins were collected to detect the expression of FAK and phosphorylated FAKY397.
[0179] 2) Combination of FAK knockout and doxorubicin produces synergistic tumor killing effects In vitro experiments were used to detect the effect of 50 nM FAK siRNA knockout and 3 μM doxorubicin on cell killing in ovarian cancer cells SK-OV-3. Cell death was photographed after 48 hours.
[0180] 3) The combination of FAK knockout and doxorubicin can effectively induce ICD effect in ovarian cancer cells SK-OV-3 In vitro experiments were carried out to detect whether FAK knockout and doxorubicin combined for 48 hours could effectively enhance the release of Calreticulin and Annexin A1, the main targets of ICD, from cells.
[0181] Test materials: Drugs used in this study: FAK siRNA was provided by GenePharma and the sequence is shown in the table below. Doxorubicin was provided by MCE. FAKsiRNA:GGGCAUCAUUCAGAAGAUATT UAUCUUCUGAAUGAUGCCCTT
[0182] Antibodies used in this study: Recombinant Alexa Fluor® 488 fluorescent Anti-HMGB1 antibody (Abcam, ab195010). Recombinant Alexa Fluor® 647 fluorescent Anti-Calreticulin antibody (Abcam, ab196159). Annexin A1 rabbit antibody (Cell signaling technology, 32934S). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) (Cell signaling technology, 4412). FAK antibody (CST, 3285S). Phospho FAKY397 antibody (Thermo fisher, 44-624G). HRP-labeled Alpha tubulin antibody (Proteintech, HRP-66031) Experimental equipment: Fluorescence microscope (Olympus U-HGLGPS). Chemiluminescence imaging device (BIORAD chemidoc touch). Test Results: 1) FAK knockout by FAK siRNA and detection of knockout efficiency SK-OV-3 cells were transfected with 50 nM FAK siRNA. Lipofectamine 3000 was used as the transfection reagent. Downstream combination use and ICD biomarker experiments can be performed 24 hours after transfection. SK-OV-3 cell proteins were collected 72 hours after transfection, and western blot was performed to detect the amount of phosphorylated FAKY397, FAK, and Alpha tubulin. The transfection effect is based on the knockout status of the protein and is shown in Figure 1. FAK siRNA has a highly significant knockout effect on phosphorylated FAKY397 and total FAK protein.
[0183] 2) Combination of FAK knockout and doxorubicin produces synergistic tumor killing effects SK-OV-3 cells were transfected with 50 nM FAK siRNA for 24 hours, followed by the addition of 3 μM doxorubicin. After 48 hours of co-culture, the cells were photographed and found that the combined use of FAK knockout and doxorubicin produced a highly significant synergistic killing effect on tumor cells. The results are shown in Figure 2.
[0184] 3) The combined use of PLD and FAK knockout significantly enhanced the release and exposure of calreticulin and Annexin A1, which are targets of the ICD of SK-OV-3. SK-OV-3 cells were treated with a combination of 3μM doxorubicin and 50nM FAK siRNA, and 48 hours later, fluorescent staining was performed using Hoechst 33342, Calreticulin, and Annexin A1 antibodies. The results, as shown in Figure 3, showed that the release and exposure of Calreticulin and Annexin A1 were both significantly enhanced when comparing the combination group with the single drug group.
[0185] Test conclusion: FAK knockdown can significantly enhance the cell killing effect of doxorubicin on ovarian cancer cells SK-OV-3. Experiments detecting ICD markers showed that FAK knockdown can significantly enhance the exposure and release of DAMPs markers Calreticulin and Annexin A1, suggesting that FAK knockdown can effectively enhance immunogenic cell death of ovarian cancer cells.
[0186] Example 2: Study on IN10018 enhancing immunogenic cell death of ovarian cancer cells in response to doxorubicin Experimental Design: 1) Combination of IN10018 and doxorubicin produces synergistic tumor killing effects In vitro experiments were used to detect the cell killing curves of IN10018 and doxorubicin in ovarian cancer cells SK-OV-3 and determine the IC50 value. The cytotoxicity effects of the combination of different doses of doxorubicin with 3μM IN10018 were investigated. Annexin V method was used to detect the apoptotic response of the drugs used individually and in combination. Student's t-test was used for statistical studies. **** means that the P value is less than 0.001.
[0187] 2) The combination of IN10018 and doxorubicin can effectively induce ICD effect in ovarian cancer cells SK-OV-3 In vitro experiments were carried out to detect whether IN10018 could effectively enhance the release of Calreticulin, HMGB1 and Annexin A1, the main targets of ICD, from cells after the combination of IN10018 and doxorubicin for 48 hours.
[0188] Test materials: 1) Drugs used in this experiment IN10018 was synthesized according to the method of patent WO2010058032. Doxorubicin was provided by MCE.
[0189] 2) Antibodies used in this experiment Recombinant Alexa Fluor® 488 fluorescent Anti-HMGB1 antibody (Abcam, ab195010). Recombinant Alexa Fluor® 647 fluorescent Anti-Calreticulin antibody (Abcam, ab196159). Annexin A1 rabbit antibody (Cell signaling technology, 32934S). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) (Cell signaling technology, 4412).
[0190] 3) Kits used in this experiment Annexin V Cell Apoptosis Kit (Abbkine, KTA0002).CCK8 Cell Viability Reagent (Cellor lab, CX001).
[0191] Experimental equipment: Microplate reader (Molecular devices M3). Fluorescence microscope (Olympus U-HGLGPS). Flow cytometer (BD LSRFortessa X-20).
[0192] Test Results: 1) IC50 curves for single agents, IN10018 and doxorubicin, against SK-OV-3 A 96-well cell plate is laid with 5000 SK-OV-3 cells / well, and after 24 hours, the drug is added with a maximum concentration of 20 μM, and serially diluted with 3-fold concentration, a total of 9 concentrations are set, with the lowest concentration being 0.3 nM. After incubating the drug with the cells for 72 hours, 10 μL of CCK8 solution is added to each well, and after incubating for 2 hours in a 37 degree 5% carbon dioxide incubator, the absorbance wavelength is set to 450 nm using a microplate reader to read the values. The values read were compared with the DMSO control group and plotted using Graphpad 8.0. The IC50 of IN10018 is 10 (μM), and the IC50 of doxorubicin is 0.3 (μM), and the results are shown in Figure 4.
[0193] 2) Synergistic killing effect of the combination of doxorubicin at different doses and 3 μM IN10018 on SK-OV-3 5000 SK-OV-3 cells / well were plated in a 96-well cell plate, and after 24 hours, the IC50 value of doxorubicin was used as the initial point, with 3 and 2 subdoses set on the left and right sides, respectively, and doxorubicin was combined with 3 μM IN10018 at these doses. After 72 hours, cell viability was detected by the CCK8 method. Graphpad 8.0 was used to plot the graph. The results showed that IN10018 could significantly enhance the cell killing effect of different doses of doxorubicin on ovarian cancer cells SK-OV-3 (see Figure 5).
[0194] 3) The combined use of doxorubicin and IN10018 significantly enhanced early and late apoptosis in SK-OV-3 cells SK-OV-3 cells were treated with 0.3μM or 1μM doxorubicin in combination with 3μM IN10018, and cells were collected after 48 hours, stained with Annexin V kit, and detected by flow cytometer. Q2 quadrant indicates late apoptosis, and Q3 quadrant indicates early apoptosis. The results showed that early and late apoptosis were significantly enhanced when compared with the combination group and the single drug group (see FIG. 6).
[0195] 4) The combined use of doxorubicin and IN10018 significantly enhanced the release and exposure of calreticulin, HMGB1, and Annexin A1 in the ICD targets of SK-OV-3. SK-OV-3 cells were treated with a combination of 0.3μM doxorubicin and 3μM IN10018, and 48 hours later, calreticulin, HMGB1 and Annexin A1 antibodies were used for fluorescent staining. The results showed that the release and exposure of calreticulin, HMGB1 and Annexin A1 were all significantly enhanced when comparing the combination group with the single drug group (see Figure 7).
[0196] Test conclusion: IN10018 can significantly enhance the cell killing effect of doxorubicin on ovarian cancer cells SK-OV-3. This effect is involved in enhancing early and late apoptosis. Experiments to detect ICD markers showed that IN10018 can significantly enhance the exposure and release of DAMPs markers Calreticulin, HMGB1 and Annexin A1, suggesting that IN10018 can effectively enhance the immunogenic cell death of ovarian cancer cells.
[0197] Example 3: Study on IN10018 enhancing immunogenic cell death of ovarian cancer cells in response to daunorubicin and epirubicin Experimental Design: Combination of IN10018 with Daunorubicin or Epirubicin can effectively induce ICD effect in ovarian cancer cells SK-OV-3 In vitro experiments were carried out to detect whether cells could effectively increase calreticulin, the main target of ICD, after combining IN10018 with Daunorubicin or Epirubicin for 48 hours.
[0198] Test materials: 1) Drugs used in this experiment IN10018 was synthesized according to the method of patent WO2010058032. Daunorubicin was provided by MCE. Epirubicin was provided by MCE.
[0199] 2) Antibodies used in this experiment Fluorescent Anti-Calreticulin antibody (Abcam, ab196159).
[0200] Experimental equipment: Fluorescence microscope (Olympus U-HGLGPS).
[0201] Test Results: The combined use of daunorubicin or epirubicin with IN10018 significantly enhanced the release and exposure of calreticulin at the ICD target of SK-OV-3.
[0202] SK-OV-3 cells were treated with a combination of 0.3μM Daunorubicin or Epirubicin and 3μM IN10018, and 48 hours later, calreticulin antibody was used for fluorescent staining. The results showed that both the release and exposure of calreticulin were significantly enhanced when comparing the combination group with the single drug group (see Figure 8).
[0203] Test conclusion: Experiments detecting ICD markers showed that IN10018 could significantly enhance the exposure and release of the DAMPs marker Calreticulin, suggesting that IN10018 could effectively enhance immunogenic cell death induced by Daunorubicin or Epirubicin.
[0204] Example 4: Study on Defactinib enhancing immunogenic cell death of ovarian cancer cells in response to doxorubicin Experimental Design: 1) Combination of defactinib and doxorubicin produces synergistic tumor killing effect The cytotoxic effect of the combined use of different doses of doxorubicin and 3 μM defactinib is examined.
[0205] 2) The combination of defactinib and doxorubicin can effectively induce the ICD effect in ovarian cancer cells SK-OV-3 In vitro experiments were carried out to detect whether defactinib and doxorubicin, when used in combination for 48 hours, could effectively enhance the release of calreticulin, HMGB1 and Annexin A1, which are the main targets of ICD, from cells.
[0206] Test materials: 1) Drugs used in this experiment Defactinib is provided by DC chemicels. Doxorubicin is provided by MCE.
[0207] 2) Antibodies used in this experiment Recombinant Alexa Fluor® 488 fluorescent Anti-HMGB1 antibody (Abcam, ab195010). Recombinant Alexa Fluor® 647 fluorescent Anti-Calreticulin antibody (Abcam, ab196159). Annexin A1 rabbit antibody (Cell signaling technology, 32934S). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) (Cell signaling technology, 4412).
[0208] 3) Kits used in this experiment CCK8 cell viability reagent (Cellor lab, CX001).
[0209] Experimental equipment: Microplate reader (Molecular devices M3) Fluorescence microscope (Olympus U-HGLGPS).
[0210] Test Results: 1) Synergistic killing effect of the combination of doxorubicin at different doses and 3 μM defactinib on SK-OV-3 5000 SK-OV-3 cells / well were plated in a 96-well cell plate, and after 24 hours, the IC50 value of doxorubicin was used as the initial point, with three and two subdoses set on the left and right sides, respectively, and these doses of doxorubicin were combined with 3 μM of Defactinib. After 72 hours, the cell viability was detected by the CCK8 method. Graphpad 8.0 was used to plot the graph. The results showed that Defactinib could significantly enhance the cell killing effect of different doses of doxorubicin on ovarian cancer cells SK-OV-3 (see Figure 9). Student's t-test was used for statistical studies, *** indicates a P value less than 0.005; **** indicates a P value less than 0.001.
[0211] 2) The combination of doxorubicin and defactinib significantly improved the release and exposure of calreticulin, HMGB1, and Annexin A1, which are targets of ICD in SK-OV-3. SK-OV-3 cells were treated with a combination of 1 μM doxorubicin and 3 μM defactinib, and fluorescent staining was performed using calreticulin, HMGB1, and Annexin A1 antibodies 48 hours later. The results showed that the release and exposure of calreticulin, HMGB1, and Annexin A1 were all significantly enhanced when comparing the combination group with the single drug group (see Figure 10).
[0212] Test conclusion: Defactinib can significantly enhance the cell killing effect of doxorubicin on ovarian cancer cells SK-OV-3. Experiments to detect ICD markers showed that Defactinib can significantly enhance the exposure and release of DAMPs markers Calreticulin, HMGB1, and Annexin A1, suggesting that Defactinib can effectively enhance the immunogenic cell death of ovarian cancer cells.
[0213] Example 5: Efficacy study of IN10018 and doxorubicin in colon cancer CT26 cell line Test materials: 1) Drugs used in this experiment Doxorubicin was provided by MCE, Cat No.: HY-15142, Lot No.: 97451. 2) Antibodies used in this experiment Recombinant Alexa Fluor® 647 fluorescent Anti-Calreticulin antibody (Abcam, Cat No.: ab196159, Lot No.: CR33676773). Annexin-Modulation Assay Kit (Beyotime, Cat No.: C1062L, Lot No.: 021921210811).
[0214] Testing Method: CT26 cells were cultured in RPMI 1640 (Shanghai Yuanpei, Cat No.: L210KJ, Lot No.: F210916) + 10% FBS (Gibco, Cat No.: 10099-141c, Lot No.: 2158737cp), passaged twice, and when the cell condition was good, the culture plate was placed in a 24-well plate. After the cells were spread for 24 hours, 4 groups were set up, the first group was the control group, with the addition of culture medium, the second group was IN10018, with a concentration of 5 μM, the third group was doxorubicin (Doxorubicin, MCE), with a concentration of 1 uM, and the fourth group was the combination of IN10018 (5 μM) and doxorubicin (1 μM). The drugs were mixed and incubated at 37 °C with 5% CO 2 The cells were cultured in an incubator for 48 hours.
[0215] Experimental Results After 48 hours of drug action, the cells were observed under a microscope and photographed to confirm the cell killing effect. Then, the cells were collected for flow analysis, and the cells were washed twice using flow buffer (PBS + 2% FBS) and 0.5 μl of AF647, and anti-calreticulin antibody (abcam) was added to each well and mixed. After incubation at 4 ° C and under light-shielded conditions, 20 min incubation was performed, and then flow buffer was added, and 195 μl of Annexin-V-FITC conjugate was added using Annexin staining kit (Beyotime), and mixed with the cells by pipetting, and then 5 μl of Annexin-V-FITC antibody was added and mixed gently, and finally 10 μl of PI dye was added and mixed, and incubated at room temperature in the dark for 15 min, and the sample was sent to a flow cytometer for signal measurement.
[0216] As shown in Figure 11, microscopic observation of cells showed that the doxorubicin single agent group and the two-drug combination group had cell killing effects, the two-drug combination group had the most significant cell killing effect, and the control group and IN10018 group had good cell conditions, as shown in Figure 12a and Figure 12b. Flow cytometer analysis results showed that the CRT positive rate and Annexin-V positive rate of the two-drug combination group were significantly higher than those of the single agent group and the control group.
[0217] Example 6: Study on the in vivo antitumor efficacy of IN10018 in a BALB / c mouse subcutaneous allograft tumor model of colon cancer CT26 cells Test materials: Mice: Female BALB / c mice aged 6-8 weeks were purchased from Shanghai Silica Laboratory Animal Co., Ltd.
[0218] After the animals arrived, they were adapted to the experimental environment before the experiment began. The animals were kept in IVC (independent ventilation system) cages (4 animals per cage) in an SPF-grade animal room. All cages, bedding and drinking water must be sterilized before use. All experimenters should wear protective clothing and latex gloves when operating in the animal room. The animal information card for each cage should indicate the number of animals in the cage, sex, breed, date of receipt, dosing schedule, experiment number, group and start date of the experiment. Cages, food and drinking water were changed twice a week. The breeding environment and light exposure conditions are as follows:
[0219] Temperature:20~26 o C. Humidity: 40~70%.
[0220] Light cycle: 12 hours light, 12 hours no light.
[0221] Cage: Made of polycarbonate, volume 300 mm x 180 mm x 150 mm. The bedding was corn cobs and was changed twice a week.
[0222] Diet: Experimental animals had free access to diet (irradiation-sterilized dry pellet diet) throughout the experimental period.
[0223] Drinking water: Experimental animals had free access to sterile water.
[0224] Animal tagging: Experimental animals were identified by ear tags.
[0225] Compound information is shown in Table 1. Table 1. Compound information [Table 2]
[0226] Colon cancer cells CT26 (derived from the Cell Bank of the Chinese Academy of Sciences, product number: TCM37) were preserved and subcultured by Huiyuan Biotechnology (Shanghai) Co., Ltd. The cells were cultured in a monolayer in vitro under the following conditions: RPMI-1640 medium supplemented with 10% fetal bovine serum, 37°C, 5% CO 2 The cells were cultured in an incubator. They were passaged 2-3 times a week by general digestion with pancreatin-EDTA. When the cells were in the exponential growth phase and 80%-85% saturation, they were harvested, counted, and inoculated.
[0227] Cell inoculation and grouping 2×10 5 0.1 mL of the cell suspension containing 10 cells was inoculated subcutaneously into the right back of each mouse. Tumor volumes were ∼38 mm. 3 When the tumor volume reached 100 μg / kg (9 days after cell inoculation), the mice were randomly divided into groups based on the tumor volume and administered the treatment. The grouping information is shown in Table 2. Table 2. Administration schedule of test substances to CT26 mouse xenograft tumor model [Table 3] Notes: 1. Number of mice in each group 2. Dosing volume: 10mL / kg based on the mouse body weight. When the body weight loss exceeded 15%, the animals were discontinued, and the administration was resumed after the body weight loss recovered to 10%.
[0228] Preparation of test substances Details are shown in Table 3. Table 3. Preparation of test substances [Table 4]
[0229] Daily observation of laboratory animals The establishment of this experimental protocol and any modifications were approved by the evaluation of the Kigen Bio IACUC. The use and welfare of experimental animals were carried out in accordance with AAALAC regulations. The health and mortality of the animals were monitored daily, and regular inspections were conducted to observe the growth of tumors and the effects of drug treatment on the animals' daily behavioral abilities, such as behavioral activity, food and water intake (visual inspection only), changes in body weight, external signs, or other abnormal conditions. The animals were given daily care and artificially assisted urination. Based on the number of animals in each group, the number of deaths and side effects of animals in each group were recorded.
[0230] End of experiment If the animal's health condition continues to deteriorate or the tumor volume exceeds 2000 mm 3 If the weight of the animal exceeds 100 kg / m2, or if the animal is in severe disease or pain, euthanasia is required. If any of the following conditions are met, a veterinarian should be contacted and euthanasia performed: - Significant weight loss, with weight loss exceeding 20% - Inability to eat and drink freely - The mean tumor volume in the control group is 2000 mm2 or greater 3 The experiment is terminated when the animal exhibits the following clinical signs: erect fur, arched back, pale ears, nose, eyes or feet, labored breathing, convulsions, persistent diarrhea, dehydration, slowness, vocalization, and persistent deterioration.
[0231] Tumor measurements and laboratory endpoints Tumor diameters were measured with a caliper three times a week. The formula for calculating tumor volume was V = 0.5 × a × b 2 where a and b represent the long and short diameters of the tumor, respectively.
[0232] The tumor growth inhibition rate (TGI) (%) was calculated based on the tumor volume on the first day after grouping according to the following formula: TGI (%) = [1-(mean tumor volume of a given treatment group-mean tumor volume at the start of treatment of that treatment group) / (mean tumor volume of the solvent control group-mean tumor volume at the start of treatment of the solvent control group)] x 100%.
[0233] statistical analysis Statistical analysis was performed using SPSS 24 software based on tumor volume and tumor weight at the end of the study. Comparison between multiple groups was performed using one-way ANOVA test, for example, when variance was homogeneous (F>0.05), Tukey test was used, and when variance was not homogeneous (F<0.05), Games-Howell test was used. P<0.05 was considered as a significant difference.
[0234] Experimental Results In vivo efficacy of the test substance IN10018 and / or PD-L1 antibody in combination with the positive drug Doxil in a CT26 mouse colon cancer cell allograft tumor model in BALB / c mice. After cell inoculation, tumor growth was observed daily, and on the 9th day after inoculation, the tumors were divided into groups based on tumor volume. The mean tumor volume at the time of inclusion was approximately 38 mm. 3 Due to tumor burden, the control group (G1) mice were euthanized on day 28, and the PD-L1 antibody group (G3) #790 mice were euthanized on day 32. The entire experiment was terminated on day 35.
[0235] On the 28th day after group administration, the tumor volume in the control group was 2176.53 ± 491.44 mm 3 The tumor volumes in the IN10018 + Doxil (12.5 + 1.5 mg / kg), PD-L1 antibody (2.5 mg / kg), IN10018 + Doxil + PD-L1 antibody (12.5 + 1.5 + 2.5 mg / kg), and Doxil + PD-L1 antibody (1.5 + 2.5 mg / kg) treatment groups were 340.51 ± 89.1 mm, respectively. 3 , 807.22±257.97mm 3 , 88.95±33.38mm 3 and 295.53±215.08mm 3The details are shown in Table 4. Comparing the overall tumor volumes, the tumor inhibition rates (TGI) of IN10018+Doxil (12.5+1.5mg / kg), PD-L1 antibody (2.5mg / kg), IN10018+Doxil+PD-L1 antibody (12.5+1.5+2.5mg / kg) and Doxil+PD-L1 antibody (1.5+2.5mg / kg) were 85.91% (p=0.041), 64.05% (p=0.171), 97.66% (p=0.022) and 88.00% (p=0.038), respectively, as shown in Table 4. The tumor volumes at different periods for each dose group are shown in Figure 13.
[0236] Table 4. Evaluation of the tumor-inhibitory effect of the test substance on a BALB / c mouse tumor model transplanted with mouse colon cancer CT26 cells (Based on 28th day data) [Table 5] Note: Data are means ± SEM.
[0237] The experiment was carried out according to the administration schedule, and during the experiment, the animals' activities such as eating and drinking were observed every day, and the animal's weight was recorded three times a week, and the animal's weight curves are shown in Figure 14. During the entire administration period, the animals in each group did not lose weight significantly and were in good condition.
[0238] conclusion Compared with the blank control group, the IN10018+Doxil (12.5+1.5mg / kg), PD-L1 antibody (2.5mg / kg), IN10018+Doxil+PD-L1 antibody (12.5+1.5+2.5mg / kg) and Doxil+PD-L1 antibody (1.5+2.5mg / kg) treatment groups all had obvious tumor growth inhibition effects, with tumor inhibition rates (TGI) all exceeding 60%. The tumor inhibition effect of IN10018+Doxil+PD-L1 antibody (12.5+1.5+2.5mg / kg) was the best.
[0239] Example 7: Study on the in vivo antitumor efficacy of defactinib in a BALB / c mouse subcutaneous homograft tumor model of colon cancer CT26 cells Test materials: Mice: 6-8 week old female BALB / c mice were purchased from Beijing Weitong Lihua Laboratory Animal Co., Ltd. After the animals arrived, they were adapted to the experimental environment before the experiment began. The animals were kept in IVC (independent ventilation system) cages (5 per cage) in an SPF-grade animal breeding room. All cages, bedding and drinking water should be sterilized before use. All experimenters should wear protective clothing and latex gloves when operating in the animal breeding room. The animal information card of each cage should indicate the number of animals in the cage, sex, breed, date of receipt, dosing schedule, experiment number, group and start date of the experiment. Cages, food and drinking water were changed twice a week. The breeding environment and light exposure conditions are as follows:
[0240] Temperature:20~26 o C. Humidity: 40~70%.
[0241] Light cycle: 12 hours light, 12 hours no light.
[0242] Cage: Made of polycarbonate, volume 300 mm x 180 mm x 150 mm. The bedding was corn cobs and was changed twice a week.
[0243] Diet: Experimental animals had free access to diet (irradiation-sterilized dry pellet diet) throughout the experimental period.
[0244] Drinking water: Experimental animals had free access to sterile water.
[0245] Animal tagging: Experimental animals were identified by ear tags.
[0246] Compound information is shown in Table 5.
[0247] Table 5. Compound information [Table 6]
[0248] Colon cancer cells CT26 (originating from Nanjing Kebai Biotechnology Co., Ltd., product number: CBP60043) were maintained by Yingshi Biotechnology (Nanjing) Co., Ltd. The cells were cultured in a monolayer in vitro under the following culture conditions: RPMI-1640 medium supplemented with 10% fetal bovine serum, 5% CO at 37°C. 2 The cells were cultured in an incubator. They were passaged 2-3 times a week by general digestion with pancreatin-EDTA. When the cells were in the exponential growth phase and 80%-90% saturation, they were harvested, counted, and inoculated.
[0249] Cell inoculation and grouping 3×10 5 0.1 mL of the cell suspension containing 10 cells was inoculated subcutaneously into the right back of each mouse. The tumor volume was ∼81 mm. 3 When the tumor volume reached 100 μg / kg (9 days after cell inoculation), the mice were randomly divided into groups based on tumor volume and administered the treatment. The grouping information is shown in Table 6.
[0250] Table 6. Administration schedule of test substances to CT26 mouse xenograft tumor model [Table 7] Notes: 1. Number of mice in each group
[0251] 2. Dosing volume: 10mL / kg based on the mouse body weight. When the body weight loss exceeded 15%, the animals were discontinued, and the administration was resumed after the body weight loss recovered to 10%.
[0252] Preparation of test substances Details are shown in Table 7. Table 7. Preparation of test substances [Table 8]
[0253] Daily observation of laboratory animals The establishment of this experimental protocol and any modifications were both approved by the evaluation of the Yunqiao Biological IACUC. The use and welfare of laboratory animals were carried out in accordance with AAALAC regulations. The health and mortality of the animals were monitored daily, and regular inspections were conducted to observe the tumor growth and the effects of drug treatment on the animals' daily behavioral ability, such as behavioral activity, food and water intake (visual inspection only), changes in body weight, external signs, or other abnormal conditions. Based on the number of animals in each group, the number of deaths and side effects of animals in each group were recorded.
[0254] End of experiment If the animal's health condition continues to deteriorate or the tumor volume exceeds 4000mm 3 If the weight of the animal exceeds 100 kg / m2, or if the animal is in severe disease or pain, euthanasia is required. If any of the following conditions are met, a veterinarian should be contacted and euthanasia performed: - Significant weight loss, with weight loss exceeding 20% - Inability to eat and drink freely - The mean tumor volume in the control group is 4000 mm2 or greater - The mean tumor volume in the control group is 4000 mm2 or greater 3 The experiment is terminated when the animal exhibits the following clinical signs: erect fur, arched back, pale ears, nose, eyes or feet, labored breathing, convulsions, persistent diarrhea, dehydration, slowness, vocalization, and persistent deterioration.
[0255] Tumor measurements and laboratory endpoints Tumor diameters were measured with a caliper three times a week. The formula for calculating tumor volume was V = 0.5 × a × b 2 where a and b represent the long and short diameters of the tumor, respectively.
[0256] The tumor growth inhibition rate (TGI) (%) was calculated based on the tumor volume on the first day after grouping according to the following formula: TGI (%) = [1-(mean tumor volume of a given treatment group-mean tumor volume at the start of treatment of that treatment group) / (mean tumor volume of the solvent control group-mean tumor volume at the start of treatment of the solvent control group)] x 100%. statistical analysis Statistical analysis was performed using Prism Graphpad based on tumor volume and tumor weight at the end of the study. Multiple pairwise comparisons were analyzed using Two-way ANOVA test. Differences were considered significant when P<0.05.
[0257] Experimental Results In vivo efficacy of the test substances Defactinib and / or PD-L1 antibody in combination with the positive drug Doxil in a CT26 mouse colon cancer cell allograft tumor model in BALB / c mice. After cell inoculation, tumor growth was observed daily, and on the 9th day after inoculation, tumors were divided into groups based on tumor volume. The average tumor volume at the time of inclusion was approximately 81 mm. 3 Due to tumor burden, mice in all groups were euthanized on day 24 after inoculation, i.e., day 15 after group administration, and the entire experiment was terminated.
[0258] On the 15th day after group administration, the tumor volume in the control group was 3920.2 ± 1697.5 mm 3 The tumor volumes in each treatment group, Defactinib + Doxil (25 + 1.5 mg / kg), Doxil alone (1.5 mg / kg), PD-L1 antibody (10 mg / kg), Doxil + PD-L1 antibody (1.5 + 10 mg / kg), and Defactinib + Doxil + PD-L1 antibody (25 + 1.5 + 10 mg / kg), were 2942.2 ± 1491.2 mm, respectively. 3 , 3130.9±1446.2mm 3 , 3645.2±1914.8mm 3 , 2964.6±1653.2mm 3 and 1546.5±1237.9mm 3The details are shown in Table 8. When comparing the tumor volume with the control group, the tumor inhibition rates (TGI) of Defactinib + Doxil (25 + 1.5 mg / kg), Doxil alone (1.5 mg / kg), PD-L1 antibody (10 mg / kg), Doxil + PD-L1 antibody (1.5 + 10 mg / kg), and Defactinib + Doxil + PD-L1 antibody (25 + 1.5 + 10 mg / kg) were 25.49% (p = 0.0470), 20.55% (p = 0.1513), 7.17% (p = 0.9267), 24.89% (p = 0.0547), and 61.83% (p < 0.0001), respectively. Statistical analysis was performed by comparing the total tumor volume with the Defactinib + Doxil + PD-L1 antibody (25 + 1.5 + 10 mg / kg) group, and the P values for the control group, Defactinib + Doxil (25 + 1.5 mg / kg), Doxil alone (1.5 mg / kg), PD-L1 antibody (10 mg / kg), and Doxil + PD-L1 antibody (1.5 + 10 mg / kg) groups were p<0.0001, p=0.0016, p=0.0002, p<0.0001, and p=0.0013, respectively, as shown in Table 8. The tumor volumes of each dose group at different time periods are shown in Figure 15.
[0259] Table 8. Evaluation of the tumor-inhibitory effect of the test substance on a BALB / c mouse tumor model transplanted with mouse colon cancer CT26 cells (Based on data from 15 days after group administration) [Table 9] Notes: 1. Calculations were made according to the number of days after group administration, and data are shown as mean values ± standard error. 2. * :p<0.05, **** :p<0.0001, vs. control group, Two-way ANOVA. 3. ** :p<0.01, *** :p<0.001, **** :p<0.0001, vs. Defactinib+Doxil+PD-L1 antibody (25+1.5+10mg / kg) group, Two-way ANOVA.
[0260] The experiment was carried out according to the administration schedule, and during the experiment, the animals' activities such as eating and drinking were observed every day, and the animals' body weight was recorded three times a week, and the animal weight curves are shown in Figure 16. During the entire administration period, the animals in each group did not lose weight significantly and were in good condition.
[0261] conclusion Compared with the blank control group, the Defactinib + Doxil (25 + 1.5 mg / kg) and Defactinib + Doxil + PD-L1 antibody (25 + 1.5 + 10 mg / kg) groups all had obvious tumor growth inhibition effects, and all were statistically different from the control group. The Defactinib + Doxil + PD-L1 antibody (25 + 1.5 + 10 mg / kg) group had smaller tumors than the Defactinib + Doxil (25 + 1.5 mg / kg), Doxil single agent (1.5 mg / kg), PD-L1 antibody (10 mg / kg) and Doxil + PD-L1 antibody (1.5 + 10 mg / kg) groups, and all were statistically different from these single drug groups and the two-drug combination groups, and had a better tumor growth inhibition effect than each single drug group and the two-drug combination group.
[0262] Example 8: ELISA detection of IFN-γ and Granzyme B in serum after treatment of a BALB / c mouse subcutaneous allograft tumor model of colon cancer CT26 cells with a combination treatment of the test substances Doxil and IN10018 Experimental materials The test samples are shown in Table 9. Table 9 [Table 10]
[0263] The experimental reagent information is shown in Table 10.
[0264] Table 10 [Table 11]
[0265] Experimental methods and procedures BALB / c mice (from Shanghai Lingchun Biotechnology Co., Ltd.) were used to establish the CT26 tumor cell model. The tumor volume was 40–60 mm 3 When tumor volume reached this level, subjects were randomly assigned to groups based on tumor volume and administered the treatment. Group assignment information is shown in Table 11.
[0266] Table 11: Grouping of experimental animals and dosing schedule [Table 12] Notes: 1.N: Number of mice in each group 2. Dosing volume: 10mL / kg based on the mouse body weight. When the body weight loss exceeded 15%, the animals were discontinued, and the administration was resumed after the body weight loss recovered to 10%.
[0267] Collection and preparation of mouse serum Twenty-four hours after the second dose of Doxil, animals in the four groups were bled via the orbit, the blood was placed in a collection tube without anticoagulant, and left at room temperature for 30-60 minutes to allow natural coagulation. Once the blood had clotted, it was centrifuged at 1000 rpm for 10 minutes at 4°C. The upper layer of serum was transferred to a new collection tube and stored in a refrigerator at -80°C.
[0268] Detection of IFN-γ in mouse serum Add 100 μl of sample to the corresponding wells (prepared by diluting the sample 5-fold with sample diluent), seal the reaction wells with a transparent microplate sealer, incubate at room temperature for 120 minutes, wash the plate 5 times, place on thick absorbent paper and tap dry, add 100 μl of biotinylated antibody to the wells, seal the reaction wells with a transparent microplate sealer, incubate at room temperature for 60 minutes, wash the plate 5 times, place on thick absorbent paper and tap dry, add 100 μl of horseradish peroxidase-labeled streptavidin to the wells, seal the reaction wells with a white microplate sealer, and incubate at room temperature for 20 minutes in the dark. If the room temperature is low (below 25°C), the incubation time should be appropriately extended, the plate should be washed 5 times, and finally placed on thick absorbent paper and patted dry, and 100μl / well of the color developer TMB solution should be added, and the reaction wells should be sealed with a microplate sealer (white), and incubated at room temperature for 15-20 minutes in the dark; if the room temperature is low, the incubation time should be appropriately extended, and the standard can be incubated until a very significant color change appears; if the sample concentration is high enough, a significant color change appears, and 50μl / well of the end solution should be added, and the A450 value should be measured immediately after uniform mixing.
[0269] Granzyme B detection in mouse serum Add 100 μl of sample to the corresponding wells (prepared by diluting the sample 5-fold with sample diluent), seal the reaction wells with a microplate sealer (transparent), incubate at 37°C for 90 minutes, do not wash, add 100 μl of biotinylated antibody to the corresponding wells, seal the reaction wells with a microplate sealer (transparent), incubate at 37°C for 60 minutes, wash the plate three times, and finally place on thick absorbent paper and tap dry. Add 100 μl of Avidin-Biotin-Peroxidase Complex (ABC) to the corresponding wells, seal the reaction wells with a microplate sealer (white), incubate at 37°C for 30 minutes in the dark, wash the plate five times, and finally place on thick absorbent paper and tap dry. Add 90 μl of chromogen TMB solution to the corresponding wells, seal the reaction wells with a microplate sealer (white), and incubate at room temperature for 15-20 minutes in the dark. If the room temperature is low, the incubation time should be appropriately extended, and the standard can be incubated until a significant color change appears. If the sample concentration is high enough, a significant color change appears, and the final solution is added at 100 μl / well, mixed uniformly, and the A450 value is immediately measured.
[0270] statistical analysis Statistical analysis was performed using Prism Graphpad software. Comparisons between multiple groups were analyzed using two-way ANOVA and Kruskal-Wallis test. Differences were considered significant when P<0.05.
[0271] Experimental Results Detection of IFN-γ in mouse serum The IFN-γ protein concentration in each group was 363.10±4.06pg / ml for the blank control, 367.24±7.34pg / ml for IN10018, 359.13±5.71pg / ml for Doxil, and 387.00±4.04pg / ml for Doxil+IN10018. When comparing the protein concentrations together with Doxil+IN10018, the Doxil+IN10018 dual-drug combination group had higher protein expression than the Doxil monotherapy group. Statistical analysis showed that the P value was p<0.001. Details are shown in Figure 17.
[0272] Granzyme B detection results in mouse serum The Granzyme B protein concentration in each group was 34.06±47.49pg / ml for the blank control, 50.48±53.08pg / ml for IN10018, 17.24±30.80pg / ml for Doxil, and 72.21±35.40pg / ml for Doxil+IN10018. When comparing the protein concentrations together with Doxil+IN10018, the Doxil+IN10018 dual-drug combination group had higher protein expression than the Doxil monotherapy group. Statistical analysis showed that the P value was p<0.05. Details are shown in Figure 18.
[0273] Experimental Results In the experiment of detecting IFN-γ protein concentration in mouse serum, each group was compared with the Doxil + IN10018 group. The Doxil + IN10018 combination group had higher protein expression than the Doxil single drug group, and statistical analysis showed that the P value was p<0.001.
[0274] In the experiment of detecting Granzyme B protein concentration in mouse serum, each group was compared with the Doxil + IN10018 group. The Doxil + IN10018 dual drug combination group had higher protein expression than the Doxil single drug group, and statistical analysis showed that the P value was p<0.05.
[0275] Example 9: Study of the induction of in vitro immunogenic cell death targeting of mouse breast cancer 4T1 cells by the test compounds doxorubicin and AMP945 Test materials: 1) Drugs used in this experiment Doxorubicin was provided by MCE, Lot No.:97451 AMP945 is provided by MCE, Lot No.:143253 2) Antibodies used in this experiment Recombinant Alexa Fluor® 647 Fluorescent Anti-Calreticulin Antibody (Abcam, Cat No.: ab196159, Lot No.: CR33676773). Annexin V-Apoptosis Detection Kit (Beyotime, Cat No.: C1062L, Lot No.: 122221220706).
[0276] Testing Method: 4T1 cells (originated from Nanjing Kebei Biotechnology Co., Ltd., Product No.: CBP60352) were incubated with RPMI 1640 (Shanghai Yuanpei, Cat No.: L210KJ, Lot No.: F210916) + 10% FBS (Gibco, Cat No.: 10099-141c, Lot No.:2158737cp), and the culture conditions were 37℃, 5% CO 2 General digestion and subculture treatment with trypsin was performed 2-3 times a week. When the cells were in the exponential growth phase and reached 80%-90% adhesion confluence, the cells were collected and plated. After trypsin digestion of 4T1 cells, the cells were collected and counted, and based on the counting results, the cells were diluted with RPMI1640+10% FBS to a dilution concentration of 50,000 cells / ml, and then plated in a 12-well cell culture plate, with 2 ml of cell suspension per well, i.e., 100,000 cells. After plating was completed, the cells were incubated at 37°C, 5% CO 2The cells were then placed in an incubator and cultured. After spreading for 24 hours, six groups were set up, the first group was the control group, with the addition of medium, the second group was AMP945 at a concentration of 3 μM, the third group was AMP945 at a concentration of 6 μM, the fourth group was doxorubicin (doxorubicin, MCE) at a concentration of 0.5 uM, the fifth group was a combination of AMP945 (3 μM) and doxorubicin (0.5 μM), and the sixth group was a combination of AMP945 (6 μM) and doxorubicin (0.5 μM). The drugs were mixed and incubated at 37°C with 5% CO. 2 The cells were cultured in an incubator for 48 hours.
[0277] Experimental Results After 48 hours of drug action, cells were collected for flow analysis, cells were washed twice with flow buffer (PBS + 2% FBS) and 0.5 μl AF647, anti-calreticulin antibody (abcam) was added to each well and mixed. Incubated at 4 ° C and under light-shielded conditions, after 20 min incubation, flow buffer was added, 195 μl Annexin-V-FITC conjugate was added using Annexin staining kit (Beyotime), mixed with cells by pipetting, then 5 μl Annexin-V-FITC antibody was added, mixed gently, and finally 10 μl PI dye was added and mixed, incubated at room temperature and light-shielded for 15 min, and the sample was sent to a flow cytometer for signal measurement.
[0278] As shown in Figures 19a and 19b, the flow cytometer analysis results showed that the CRT positive rate and Annexin-V positive rate in the two-drug combination group were significantly superior to those in the single-drug group and the control group.
[0279] Example 10: Study of the induction of in vitro immunogenic cell death targeting of mouse colon cancer CT26 cells by the test compounds doxorubicin and AMP945 Test materials: 1) Drugs used in this experiment Doxorubicin was provided by MCE, Lot No.:97451 AMP945 is provided by MCE, Lot No.:143253 2) Antibodies used in this experiment Recombinant Alexa Fluor® 647 Fluorescent Anti-Calreticulin Antibody (Abcam, Cat No.: ab196159, Lot No.: CR33676773). Annexin V-Apoptosis Detection Kit (Beyotime, Cat No.: C1062L, Lot No.: 122221220706).
[0280] Testing Method: CT26 cells (originated from Nanjing Kebei Biotechnology Co., Ltd., Product No.: CBP60043) were incubated with RPMI 1640 (Shanghai Yuanpei, Cat No.: L210KJ, Lot No.: F210916) + 10% FBS (Gibco, Cat No.: 10099-141c, Lot No.:2158737cp), and the culture conditions were 37℃, 5% CO 2 General digestion and subculture treatment with trypsin was performed 2-3 times a week. When the cells were in the exponential growth phase and reached 80%-90% adhesion confluence, the cells were collected and plated. After trypsin digestion of CT26 cells, the cells were collected and counted, and based on the counting results, the cells were diluted with RPMI1640+10% FBS to a dilution concentration of 50,000 cells / ml, and then plated in a 12-well cell culture plate, with 2 ml of cell suspension per well, i.e., 100,000 cells. After plating was completed, the cells were incubated at 37°C, 5% CO 2 The cells were then placed in an incubator and cultured. After spreading for 24 hours, six groups were set up, the first group was the control group, to which medium was added, the second group was AMP945 at a concentration of 0.75 μM, the third group was AMP945 at a concentration of 1.5 μM, the fourth group was doxorubicin (doxorubicin, MCE) at a concentration of 0.5 uM, the fifth group was a combination of AMP945 (0.75 μM) and doxorubicin (0.5 μM), and the sixth group was a combination of AMP945 (1.5 μM) and doxorubicin (0.5 μM). The drugs were mixed and incubated at 37°C with 5% CO. 2 The cells were cultured in an incubator for 48 hours.
[0281] Experimental Results After 48 hours of drug action, cells were collected for flow analysis, cells were washed twice with flow buffer (PBS + 2% FBS) and 0.5 μl AF647, anti-calreticulin antibody (abcam) was added to each well and mixed. Incubated at 4 ° C and under light-shielded conditions, after 20 min incubation, flow buffer was added, 195 μl Annexin-V-FITC conjugate was added using Annexin staining kit (Beyotime), mixed with cells by pipetting, then 5 μl Annexin-V-FITC antibody was added, mixed gently, and finally 10 μl PI dye was added and mixed, incubated at room temperature and light-shielded for 15 min, and the sample was sent to a flow cytometer for signal measurement.
[0282] As shown in Figures 20a and 20b, the flow cytometer analysis results showed that the CRT positive rate and Annexin-V positive rate in the two-drug combination group were significantly superior to those in the single-drug group and the control group.
[0283] Example 11: Clinical study of IN10018 in combination with PLD and anti-PD-1 for the treatment of ovarian cancer IN10018 in combination with polyethylene glycol liposomal doxorubicin (PLD) and anti-PD-1 antibody to treat platinum-resistant recurrent ovarian cancer is being evaluated in a phase Ib / II clinical study (IN10018-010) conducted in China. The IN10018 was its tartrate salt, the PLD was commercially available liposomal doxorubicin hydrochloride injection (generic name), and the anti-PD-1 antibody was commercially available toripalimab in the study. Study subjects received 100 mg of IN10018 orally once daily (QD) and 40 mg / m PLD. 2 Patients were randomly assigned to receive 100 mg / kg intravenously once every 4 weeks (Q4W) and 3 mg / kg toripalimab once every 2 weeks (Q2W). One treatment cycle lasted 28 days.
[0284] By November 30, 2022, 41 patients with various solid tumors had been enrolled in the study and treated with the triple combination (IN10018 + PLD + anti-PD-1), of which 24 were patients with platinum-resistant recurrent ovarian cancer. All 41 patients had received at least one drug treatment and were included in the safety analysis. Of the 24 patients with platinum-resistant recurrent ovarian cancer in the group, 13 patients had initial tumor imaging evaluation data and were included in the treatment efficacy analysis.
[0285] The baseline characteristics of the 24 platinum-resistant recurrent ovarian cancer patients in the group are summarized in Table 12.
[0286] Table 12: Summary of baseline characteristics of the 26 platinum-resistant recurrent ovarian cancer patients in the study [Table 13]
[0287] Treatment effect The study evaluated the antitumor efficacy of a triple combination (IN10018+PLD+anti-PD-1) treatment in platinum-resistant recurrent ovarian cancer subjects by evaluating the change in tumor burden over time based on tumor imaging. The study prioritized imaging with contrast-enhanced computed tomography (CT). The abdomen and pelvis could be examined with contrast-enhanced magnetic resonance imaging (MRI) if there are contraindications to the use of iodinated contrast CT. MRI is the study of choice for brain imaging, and other imaging techniques such as PET / CT and bone scans may be used if necessary.
[0288] Imaging during the screening period must have been performed within 28 days prior to study treatment assignment. During the study, subjects underwent one tumor imaging study every 8 weeks (56 ± 7 days) until investigators evaluated them to detect imaging-confirmed disease progression, they initiated new antitumor treatment, they withdrew from the study, or they died (whichever occurred first).
[0289] The study will evaluate the efficacy of tumor therapy based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The efficacy indicators include objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS).
[0290] In a study of platinum-resistant recurrent ovarian cancer treated with a triple combination (IN10018 + PLD + anti-PD-1), a total of 13 patients were evaluable for efficacy, and most of them only had initial tumor imaging evaluation results, so only the efficacy data from the initial tumor evaluation are shown. Of the 13 patients who were evaluable for efficacy, 7 partial responses (PRs) were observed at the time of initial tumor evaluation, with an ORR of 53.8% (7 / 13), a DCR of 100% (13 / 13), and 83.5% (11 / 13) of patients had shrinkage of tumor target lesions.
[0291] In the conventional two-drug combination (IN10018 + PLD) treatment study, a total of 52 patients were evaluable for treatment effect, of which 24 PRs and 1 complete response (CR) were observed, and the best overall treatment effect ORR was 48.1%, while the ORR of platinum-resistant recurrent ovarian cancer treatment with the two-drug combination at the time of initial tumor evaluation was 28.8%. Compared with the two-drug combination, the three-drug combination (IN10018 + PLD + anti-PD-1) treatment significantly improved the treatment effect at the time of initial tumor evaluation, and more treatment effects require further data maturation.
[0292] Specific data details are shown in Tables 13 and 14 and FIG.
[0293] Table 13: Summary of antitumor therapeutic efficacy of two- and three-drug combinations [Table 14] Table 14: Initial tumor evaluation response list of triple drug combinations [Table 15] Best change from baseline in target lesion total diameter = (minimum target lesion total diameter after treatment - baseline target lesion total diameter) / baseline target lesion total diameter x 100%.
[0294] safety The study evaluated the safety of the triple combination (IN10018 + PLD + anti-PD-1) treatment in solid tumors, including ovarian cancer.A total of 41 patients with solid tumors in the study group included 24 patients with platinum-resistant recurrent ovarian cancer.
[0295] Safety analysis showed that the safety of the triple combination (IN10018 + PLD + anti-PD-1) treatment was overall similar to that of the double combination (IN10018 + PLD) treatment, the safety profile was comparable to the respective drug history data, and no significant increase in adverse events (AEs) was observed with the combination. The safety of the double and triple combinations is summarized in Table 15 below. Table 15: Summary of safety of dual and triple drug combinations [Table 16]
[0296] All references mentioned in the present invention are fully incorporated herein by reference in their entirety as if each were individually set forth. It should also be understood that after reading the disclosure of the present invention, a person skilled in the art may make various changes or modifications to the present invention, and that the equivalent forms thereof are also included in the scope defined by the claims of this application.
[0297] This application claims priority to Chinese Patent Application No. 202111508073.8 filed on December 10, 2021, Chinese Patent Application No. 202211160418.X filed on September 22, 2022, and Chinese Patent Application No. 202211543036.5 filed on December 2, 2022, the contents of which are incorporated by reference in their entirety into this specification and made a part of this application.
Claims
1. 1. Use of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein the FAK inhibitor, the anthracycline chemotherapeutic drug and the immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
2. A pharmaceutical combination product of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor for treating a tumor in a subject, wherein said FAK inhibitor, said anthracycline chemotherapeutic drug and said immune checkpoint inhibitor are administered simultaneously or sequentially to said subject.
3. A method for treating a tumor, comprising the step of simultaneously or sequentially administering to a subject in need thereof therapeutically effective amounts of a FAK inhibitor, an anthracycline chemotherapeutic drug and an immune checkpoint inhibitor.
4. 4. The use, pharmaceutical combination product or method according to any one of claims 1 to 3, wherein said FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and wherein the structure of said IN10018 is: [Case 1]
5. The use, pharmaceutical combination product or method according to any one of claims 1 to 4, wherein said anthracycline chemotherapeutic drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
6. The use, pharmaceutical combination product or method according to any one of claims 1 to 5, wherein said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
7. The use, pharmaceutical combination product or method according to any one of claims 1 to 6, wherein said FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, said anthracycline chemotherapeutic drug is doxorubicin and said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
8. The tumors include Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, and gastroesophageal junction cancer.
8. The use, pharmaceutical combination product or method of any one of claims 1 to 7, wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
9. (a) a FAK inhibitor; and (b) an anthracycline chemotherapy drug; and (c) an immune checkpoint inhibitor.
10. 10. The kit or composition of claim 9, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and the structure of IN10018 is as follows: [Case 2]
11. The kit or composition according to claim 9 or 10, wherein the anthracycline chemotherapeutic drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
12. The kit or composition according to any one of claims 9 to 11, wherein the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor, or a TIGIT inhibitor.
13. The kit or composition according to any one of claims 9 to 12, wherein the FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof, the anthracycline chemotherapeutic drug is doxorubicin, and the immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
14. The kit or composition according to any one of claims 9 to 13, for use as a medicament.
15. FAK inhibitors enhance immunogenic cell death induced by anthracycline chemotherapeutic drugs in the treatment of tumors.
16. 16. The use, FAK inhibitor or method of claim 15, wherein said anthracycline chemotherapeutic drug is doxorubicin, epirubicin, daunorubicin, preferably doxorubicin.
17. 17. The use, FAK inhibitor or method according to claim 15 or 16, wherein the FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and wherein the structure of IN10018 is: [C3]
18. 1. Use of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor in the manufacture of a medicament for treating a tumor in a subject, wherein the FAK inhibitor, doxorubicin and immune checkpoint inhibitor are administered simultaneously or sequentially to the subject.
19. A pharmaceutical combination product of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor for treating a tumor in a subject, wherein said FAK inhibitor, said doxorubicin and said immune checkpoint inhibitor are administered to said subject simultaneously or sequentially.
20. A method for treating a tumor, comprising the step of simultaneously or sequentially administering to a subject in need thereof therapeutically effective amounts of a FAK inhibitor, doxorubicin and an immune checkpoint inhibitor.
21. 21. The use, pharmaceutical combination product or method according to any one of claims 18 to 20, wherein said FAK inhibitor is IN10018, Defactinib, GSK2256098, PF-00562271, VS-4718, APG-2449, AMP945, AMP886 or a pharma- ceutically acceptable salt thereof, preferably IN10018, Defactinib, AMP945 or a pharma- ceutically acceptable salt thereof, more preferably IN10018 or a pharma- ceutically acceptable salt thereof, in particular IN10018 tartrate, and wherein the structure of said IN10018 is: [C4]
22. The use, pharmaceutical combination product or method according to any one of claims 18 to 21, wherein said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody, a PD-1 / PD-L1 small molecule inhibitor or a TIGIT inhibitor.
23. The use, pharmaceutical combination product or method according to any one of claims 18 to 22, wherein said FAK inhibitor is IN10018 or a pharma- ceutically acceptable salt thereof and said immune checkpoint inhibitor is an anti-PD-1 / PD-L1 antibody or a PD-1 / PD-L1 small molecule inhibitor, in particular toripalimab.
24. The tumors include Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, and the like.
24. The use, pharmaceutical combination product or method of any one of claims 18 to 23, wherein the tumor is acute myeloid leukemia, melanoma, thyroid cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, ovarian cancer, fibrosarcoma, gastric cancer, non-small cell lung cancer or cholangiocarcinoma, and further wherein the tumor is ovarian cancer or colon cancer.
